SECURITIES EXCHANGE ACT OF 1934
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2025 | $60.00 | Buy | Canaccord Genuity |
| 5/16/2025 | $62.00 | Buy | BTIG Research |
| 5/14/2025 | $48.00 | Hold → Buy | Needham |
| 4/14/2025 | Hold | Needham | |
| 5/22/2024 | $60.00 | Buy → Neutral | Citigroup |
| 8/31/2023 | $75.00 | Overweight | JP Morgan |
| 6/29/2023 | $79.00 | Buy | Citigroup |
| 10/14/2022 | $90.00 | Overweight | Stephens |
Canaccord Genuity initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $60.00
BTIG Research initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $62.00
Needham upgraded Establishment Labs from Hold to Buy and set a new price target of $48.00
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750830. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at ww
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the publication of "The 3-Year Results of a 100-Patient Prospective Study of Safety and Effectiveness of Mia Femtech" in the Aesthetic Surgery Journal. The study showed a very low rate of complications, with no reports of capsular contracture (Baker Grade III/IV), implant rupture (including a 33-patient MRI cohort), nipple or breast sensitivity loss, incision-related complications, infection, seroma, rippling, hematoma, or BIA-ALCL; the reoperation rate at 3 years was 1%. Patient and surgeon satis
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
SCHEDULE 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750830. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at ww
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the United States. 2025 revenue guidance increased to $208 million to $212 million from $205 million to $210 million, year over year growth of 25%–28%, with at least $40 million in US Motiva revenue. Second quarter gross ma
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establ
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision
Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)